---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-24-000026"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:52:14.698269+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Humacyte prices $40.2M public offering of 13.4M shares at $3.00 per share

## Summary
- Offering of 13,400,000 shares at $3.00/share; gross proceeds $40.2M before underwriting discounts.
- Underwriters have 30-day option to buy up to 2,010,000 additional shares.
- Net proceeds ~$37.4M (or ~$43.1M if option exercised); closing expected March 5, 2024.
- Proceeds to fund BLA for HAVs in vascular trauma, pipeline advancement, and commercial infrastructure.
- TD Cowen and Cantor are joint book-running managers; BTIG is lead manager.

## SEC filing metadata
- accession: 0001818382-24-000026
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000026/0001818382-24-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000026/huma-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-24-000026
- JSON: https://secwatch.observer/filing/0001818382-24-000026.json
- Plain text: https://secwatch.observer/filing/0001818382-24-000026.txt

## Key facts
- Material Agreements
  Humacyte, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein valued at approximately $37.4 million (effective 2024-02-29).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein
  - Value: approximately $37.4 million
  - Effective: 2024-02-29
  source text: On February 29, 2024, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) of 13,400,000 shares of the Company’s common stock, $0.0001 par value per share, at a price to the public of $3.00 per share (the “Firm Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000026/0001818382-24-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.